Poly Medicure Limited has informed the Exchange regarding a press release dated August 08, 2025, titled "Press Release for the Unaudited Financial Results for the quarter ended 30th June, 2025".
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure reported Q1 FY26 consolidated total income of Rs 444.9 Cr, up 10.7% YoY, driven by strong domestic revenue growth of 20.1%. Profit after tax rose 25.5% to Rs 93.1 Cr, with PAT margin expanding by 250bps to 20.9%. Gross profit margin improved by 170bps to 68.4%, while operating EBITDA margin slightly contracted by 70bps to 26.3%. The renal care business posted robust 46.2% YoY growth, with 1,350+ stents implanted and a new wholly-owned subsidiary established in Brazil. The company maintains a zero net debt position with liquidity of Rs 1,248.6 Cr and has spent Rs 95 Cr on capex in Q1 against a full-year budget of Rs 250 Cr. International revenue declined 0.9% due to geopolitical tensions and tariff headwinds.
Strong PAT growth and margin expansion, combined with a debt-free balance sheet and healthy domestic momentum, are positive signals for shareholders. However, slight EBITDA margin compression and weak international growth amid tariff/geopolitical headwinds are minor concerns to watch.